Trials / Completed
CompletedNCT00879554
A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors
A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CVX-045 | Weekly, intravenous dose |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-03-01
- Completion
- 2010-11-01
- First posted
- 2009-04-10
- Last updated
- 2010-12-13
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00879554. Inclusion in this directory is not an endorsement.